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i.org/1reduction therapy in patients with drug-refractory hypertrophic obstructive cardiomyopa-
thy. This study aimed to evaluate the outcome of alcohol septal ablation (ASA) using an
intravenous nitroglycerin test (IV-NTG). Of consecutive 156 patients, after excluding cases
of severe valvular disease and repeat septal reduction therapy, we investigated the clinical
characteristics of patients with labile obstruction (n [ 32) and the outcomes after ASA
using the IV-NTG test; comparisons were made with those exhibiting basal obstruction
(a resting gradient of ‡30 mm Hg). The patients with labile obstruction had less left ven-
tricular mass (141 – 47 vs 182 – 59 g, p[ 0.003) and less brain natriuretic peptide values
(414 – 576 vs 744 – 625 pg/ml, p <0.001) than those with basal obstruction. Immediately
after ASA, the gradients improved from 15 – 7 to 5 – 5 mm Hg and the IV-NTG-provoked
gradients improved from 74 – 25 to 13 – 9 mm Hg, respectively. At 1-year follow-up, the
New York Heart Association functional class had improved from 2.7 – 0.5 to 1.3 – 0.5.
There was no sudden cardiac death during the follow-up period (5.1 – 3.0 years), and 8-
year survival free from cardiovascular death was 94%. In conclusion, patients with labile
obstruction had less-severe left ventricular hypertrophy but exhibited symptoms compa-
rable to those with basal obstruction. The IV-NTG test is a useful method for rapidly
conﬁrming acute reduction of the latent gradient after the ASA procedure, and the outcome
of ASA for labile obstruction was favorable.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2015;116:945e951)Alcohol septal ablation (ASA) has been performed for
hypertrophic obstructive cardiomyopathy (HOCM) when
symptoms cannot be treated effectively even after optimi-
zation of medical treatment.1e8 To achieve optimal results
with ASA in patients with refractory symptoms related to
labile obstruction, the nature of the obstruction of the left
ventricle (LV) should be accurately described. Previous
studies focused on ASA for provocable obstruction have
been reported.9,10 Both studies demonstrated that provo-
cable obstruction could cause drug-refractory symptoms and
ASA was effective for patients without a baseline gradient.
In contemporary clinical practice, Valsalva maneuver and
postextrasystolic potentiation have been used as non-
pharmacologic methods to elucidate immediate improve-
ment of the latent gradient11; however, it is unclear which
provocation method was most appropriate during the ASAf Cardiovascular Medicine, Nippon Medical School
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Japan. Manuscript received April 14, 2015; revised
d and accepted June 6, 2015.
for disclosure information.
g author: Tel: (þ81)-3-3822-2131; fax: (þ81)-3-5685-
s: s7022@nms.ac.jp (M. Kitamura).
015 The Authors. Published by Elsevier Inc. This is an open
r the CC BY-NC-ND license (http://creativecommons.org/
4.0/).
0.1016/j.amjcard.2015.06.023procedure. The use of nitrates, which mainly decrease the
LV afterload, has been described as a conveniently admin-
istered method for immediate detection of the gradient.12
Nevertheless, there have been no reports that address the
usefulness of nitrates during the ASA procedure. Therefore,
the purposes of this study were (1) to demonstrate the
clinical characteristics of labile obstruction, (2) to determine
the usefulness of the intravenous nitroglycerin (IV-NTG)
test, and (3) to conduct a follow-up study after ASA for
labile obstruction.
Methods
We reviewed the institutional registry data of patients with
drug-refractory HOCMwho underwent ASA. Of consecutive
156 patients, after excluding cases of severe valvular disease
and repeat septal reduction therapy, we investigated the
clinical characteristics of patients with labile obstruction (n¼
32) and the outcomes after ASA using the IV-NTG test,
comparisons were made with those exhibiting basal
obstruction (a resting gradient of 30 mm Hg, n ¼ 120). In
this study, IV-NTG bolus tests were administered during
ASA to conﬁrm their acute effects in patients with a resting
gradient <30 mm Hg at baseline. At the initial presentation,
we had reviewed and optimized the prescribed patient med-
ications. Basically, symptomatic patients with HOCM werewww.ajconline.org
Table 1
Baseline characteristics of the study population in comparison with basal obstruction
Variable Labile Obstruction Basal Obstruction p value
(n ¼ 32) (n ¼ 120)
Age (years) 65  12 61  15 0.282
Female 25 (78%) 85 (71%) 0.508
Height (m) 1.55  0.12 1.55  0.10 0.826
Body weight (kg) 59  13 57  12 0.405
Body mass index (kg/m2) 24.3  3.3 23.6  3.9 0.215
Brain natriuretic peptide (pg/mL, normal <18.4pg/mL) 414  576 744  625 <0.001
Atrial natriuretic peptide (pg/mL, normal <43.0pg/mL) 162  188 162  127 0.691
Family history of sudden cardiac death 5 (16%) 15 (13%) 0.769
Septal thickness  30 mm 1 (3%) 6 (5%) 1.000
Ventricular Tachycardia/Fibrillation 5 (17%) 19 (16%) 0.502
Unexplained syncope 9 (28%) 30 (25%) 0.795
Abnormal blood pressure response 7/15 (47%) 9/59 (15%) 0.014
Implantable cardioverter-deﬁbrillator implantation 4 (13%) 6 (5%) 0.219
Dual chamber pacemaker implantation 2 (7%) 0 (0%) 0.043
History of congestive heart failure 7 (22%) 25 (21%) 1.000
Coronary artery disease 4 (13%) 2 (2%) 0.018
Atrial ﬁbrillation 5 (16%) 30 (25%) 0.054
Hypertension 17 (53%) 50 (42%) 0.317
Dyslipidemia 18 (56%) 54 (45%) 0.320
Diabetes mellitus 6 (19%) 8 (7%) 0.077
Smoker 9 (28%) 37 (31%) 0.162
Obstruction Type 0.814
Left ventricular outﬂow tract type 20 (63%) 81 (68%)
Mid-ventricular obstruction 3 (9%) 14 (12%)
Combined obstruction 9 (28%) 25 (21%)
New York Heart Association functional class 2.7 (0.5) 2.7 (0.5) 0.692
Anginal symptoms 18 (56%) 60 (50%) 0.691
FaintnesswSyncope 16 (50%) 54 (45%) 0.694
Aborted cardiac arrest 1 (3%) 4 (3%) 1.000
Measurements of the left-sided heart
Interventricular septum thickness (mm) 16.9  3.8 18.6  4.1 0.014
Posterior wall thickness (mm) 11.7  2.4 12.8  3.1 0.120
Left ventricular end-diastolic diameter (mm) 42.2  5.6 42.2  6.1 0.980
Left ventricular end-systolic diameter (mm) 22.9  4.3 23.9  4.8 0.320
Left atrial diameter (mm) 42.0  6.5 44.9  7.8 0.057
Mitral regurgitation area (cm2) 5.4  5.2 7.1  5.3 0.101
Left ventricular mass (g) 141  47 182  59 0.003
Number of hypertrophic segments 2.4  1.6 4.2  2.9 0.009
Medications at alcohol septal ablation procedure
Beta blockers 30 (94%) 110 (92) 1.000
Class Ia agents 27 (84%) 77 (64%) 0.033
Class III agents 0 (0%) 4 (3%) 0.580
Calcium-channel blockers 6 (19%) 34 (28%) 0.367
Angiotensin-converting enzyme inhibitors/Angiotensin receptor blockers 4 (13%) 18 (15%) 1.000
Diuretics 6 (19%) 30 (25%) 0.640
Nitrates 1 (3%) 0 (0%) 0.211
946 The American Journal of Cardiology (www.ajconline.org)given b blocker if titrated. Then, class Ia was added in pa-
tients with residual symptoms to improve gradient. Patients
were considered as ASA candidates if symptoms were life
limiting (New York Heart Association [NYHA] functional
class IIm to IV) after optimization of medication and a pro-
voked gradient >50 mm Hg was conﬁrmed by at least 1
method during simultaneous pressure recordings as
described in the following. We carefully excluded patients
with subaortic stenosis, abnormal insertion of papillary
muscle, extreme elongation of anterior mitral leaﬂet and large
apical aneurysm. All patients who underwent ASA had beenconsecutively assigned to the institutional registry database at
the Nippon Medical School Hospital. The institutional re-
view committee approved the study. All patients gave written
informed consent.
Diagnosis of hypertrophic cardiomyopathy (HCM) has
been established by transthoracic echocardiography (TTE).
The deﬁnition of HCM in echocardiography was based on
the presence of a maximal LV wall thickness 15 mm7 and
the absence of other conditions that might explain left
ventricular hypertrophy (LVH) during the clinical course.
LV cavity size, LV wall thickness, and left atrial diameter
Table 2
Details of the alcohol septal ablation procedure for patients with labile
obstruction
Interval from initial presentation to procedure (days) 188 [59e465]
No of ablated branches
One branch 22 (69%)
Two branches 6 (19%)
3 branches 4 (13%)
Dosage of ethanol (ml) 2.0 [1.5e2.3]
Peak creatine phosphokinase (IU/L) 1252 [915-1542]
Peak creatine phosphokinase MB-isozyme (IU/L) 142 [120e182]
Periprocedural complications within 30 days
Transient complete atrioventricular block 4 (13%)*
Persistent complete atrioventricular block 0
Sustained ventricular tachycardia 1 (3%)*
Additional pacemaker device 1 (3%)*
Cerebral infarction 1 (3%)
Ethanol misplacement 0
Coronary vessel dissection 0
Major bleeding 0
Cardiac tamponade 0
Emergency cardiac surgery 0
Death 0
Data are expressed as median [interquartile range] or as number
(percentage).
* One patient had transient trifascicular block and drug-induced sustained
ventricular tachycardia, and received implantable cardioverter-deﬁbrillator
implantation.
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Echocardiography recommendations. LV mass and the
number of hypertrophic segments were calculated using cine
cardiac magnetic resonance. In accordance with the Amer-
ican Heart Association classiﬁcation, 17 myocardial seg-
ments were deﬁned. In this study, genetic diagnosis was not
mandatory for diagnosing clinical HCM.
We diagnosed HOCM in patients with deﬁned HCM and
intraventricular velocity 2.7 m/s on TTE (or a gradient
30 mm Hg on direct simultaneous recording) at rest or
on provocation. Hemodynamic state of intraventricular
obstruction was determined according to the American Col-
lege of Cardiology Foundation/American Heart Association
Guidelines.7 In brief, basal obstruction was deﬁned as a
consistent presence of signiﬁcant gradient (30 mm Hg) at
rest. Labile obstruction was deﬁned as a resting gradient
<30 mm Hg but a provoked gradient30 mm Hg conﬁrmed
by at least 1 of the following methods: exercise test, Valsalva
maneuver, postextrasystolic potentiation, or IV-NTG.
HOCM was stratiﬁed into 3 categories of obstruction: LV
outﬂow tract type (LVOT), midventricular type, and com-
bined type in which the patients had extended obstruction at
both LVOT and midventricular levels, conﬁrmed by TTE or
simultaneous invasive recordings. We excluded patients
who exhibited only sigmoid septum but not signiﬁcant hy-
pertrophy. We treated HCM with midventricular obstruction
similar to that with LVOT obstruction, using b blockers and
class Ia agents. Furthermore, we carefully chose the indi-
cation of ASA for patients with midventricular obstruction,
in which muscular obstruction was thought to cause their
symptoms.Symptoms were obtained from medical records of the
HCM clinic and during hospitalization. Life-limiting symp-
toms were categorized according to NYHA functional class.
Patients with NYHA functional class II were stratiﬁed into 2
groups: those with slight limitation (class IIs) and moderate
limitation (class IIm) in physical activity.13 Other clinical
data such as angina, palpitation, fainting, syncopal events,
atrial ﬁbrillation, and ventricular arrhythmias were also ob-
tained. Risk factors for sudden cardiac death, coronary risk
factors, and history of atrial ﬁbrillation and congestive heart
failure were included in baseline characteristics.
Routine coronary angiography, left ventriculography,
right-sided catheterization, and pressure studies were per-
formed. All invasive evaluations were performed under
medication. Target septal artery candidates were chosen by
coronary angiography, and the obstruction level was eval-
uated by left ventriculography. Gradient was calculated as a
peak-to-peak difference of pressures between the ascending
aorta and LV apex using a retrograde approach. Pressure
recording data were acquired by a ﬂuid-ﬁlled catheter sys-
tem from a pigtail catheter at the LV apex and a catheter
placed in the ascending aorta. Simultaneous pressure re-
cordings were made at baseline and after provocation by IV-
NTG, Valsalva maneuver, and premature ventricular
contraction (PVC) induced by pigtail catheter manipulation.
Accordingly, we used specially designed pigtail catheters
(Type Mtaka, Medikit, Tokyo, Japan) during LV apical
pressure measurements. To obtain an accurate apical LV
pressure, a total of 5 holes were made in the distal portion: 1
hole in the distal tip, 1 end hole at the end of the catheter,
and 3 side holes close to the pigtail tip. This catheter tip was
small and made of soft material to decrease catheter-induced
ventricular arrhythmias. Catheter entrapment was carefully
excluded by a test bolus injection of contrast medium.
During evaluation by catheterization of those with a
resting gradient <30 mm Hg, we acquired provoked gradi-
ents during the strain phase of Valsalva maneuver, on post-
extrasystolic potentiation, and by the IV-NTG test. To obtain
the data from IV-NTG, after administration of 0.1-mg NTG
into the central venous line, we measured the pressures of the
ascending aorta and LV apex simultaneously at the lowest
systolic blood pressure. Pressure recording was continuously
performed from the administration of NTG until the pressure
was restored to baseline level. An IV-NTGeprovoked
gradient was acquired at the peak of the vasodilator effect.
When patient has low systolic blood pressure (100w120 mm
Hg), high gradient provoked by other method with systolic
blood pressure (<100 mm Hg), or highly labile gradient,
the IV-NTG test was started with smaller doses
(0.025w0.05 mg). Immediately after ASA procedure,
IV-NTG was performed with same dosage at before ASA
procedure to conﬁrm the acute effect of ASA.
A temporary pacemaker was placed into the right
ventricle to prepare for a trifascicular block during the
procedure. Using a 6Fr or 7Fr percutaneous transluminal
coronary angioplasty (PTCA) guiding catheter and a 4Fr or
5Fr specially designed pigtail catheter, a small over-the-wire
PTCA balloon was dilated on the target branch, and selec-
tive angiography was performed to conﬁrm isolation of the
left anterior descending artery. Myocardial contrast echo-
cardiography was performed during all procedures. A small
Table 3
Changes in catheterization parameters before and after alcohol septal ablation (n ¼ 32)
Variable Baseline Intravenous nitroglycerin test p value *
Before After p value Before After p value Before After
Gradient (mm Hg) 15  7 5  5 <0.0001 74  25 13  9 <0.0001 <0.0001 <0.0001
Left ventricular pressure (mm Hg)
Systolic 160  24 158  26 0.492 172  32 134  26 <0.001 0.003 <0.0001
End-diastolic 19  6 21  7 0.243 21  6 19  6 0.090 0.263 0.153
Systemic blood pressure (mm Hg)
Systolic 145  24 153  27 0.024 100  19 120  27 0.006 <0.0001 <0.0001
Diastolic 69  9 73  12 0.098 57  11 63  14 0.069 <0.0001 <0.0001
Heart rate (/min) 58  6 61  10 0.154 59  6 63  9 0.017 0.016 0.074
Nitroglycerin dosage (mg) 0.07  0.04 0.07  0.04 0.328
Mean pulmonary capillary wedged pressure (mm Hg) 15  5 15  7 0.582
Cardiac output (L/min) 4.4  0.9 4.8  1.1 0.157
Cardiac index (L/min/m2) 2.8  0.5 3.0  0.6 0.205
* In comparison between baseline and intravenous nitroglycerin test.
948 The American Journal of Cardiology (www.ajconline.org)amount (1.0 to 2.0 ml for a single branch) of alcohol was
slowly injected (0.3 ml/min) through the lumen of the over-
the-wire PTCA balloon. Morphine chloride has been used as
an analgesic, and general anesthesia was not administered.
After the procedure, all patients were admitted to the cardiac
care unit ﬁtted with a temporary pacemaker for at least
48 hours as a prophylactic measure for the late-onset heart
block.
Continuous variables are expressed as mean  standard
deviation or median with interquartile ranges. Comparisons
of continuous variables were analyzed by ManneWhitney
U tests. Changes in categorical variables were compared
with Fisher’s exact tests. Correlations of the provoked gra-
dients between IV-NTG and post-PVC were assessed by the
Pearson test. For the 8-year survival analysis of this study
population, a KaplaneMeier curve was described, and sta-
tistical comparisons with those with basal obstruction were
performed by log-rank test. Statistical analyses were per-
formed using the SPSS software program version 20.0.0.0
(IBM Corporation, New York, New York). Statistical sig-
niﬁcance was indicated when p value <0.05.
Results
From 1998 to 2013, 186 ASA procedures were performed
in 156 patients. After exclusion of basal obstruction (resting
gradient 30 mm Hg, n ¼ 120), repeat procedures (n ¼ 33),
and severe valvular disease (n ¼ 6), 32 consecutive patients
were classiﬁed as labile obstruction. Baseline characteristics
of the study population are presented in Table 1 with com-
parison between labile obstruction and basal obstruction. No
patient developed dilated-phase HCM during the observation
period. In comparison with basal obstruction, patients with
labile obstruction showed less brain natriuretic peptide
values, less interventricular septal thickness, and more
frequent use of class Ia agents such as cibenzoline, the agent
mainly prescribed.
All ASA procedures were successfully performed
without 30-day or 1-year mortality. The details are sum-
marized in Table 2. Details of alterations in IV-NTG tests
are provided in Table 3. The increases in LV systolicpressure and LV end-diastolic pressure were converted to
decreases (þ12 to 24 and þ2 to 2 mm Hg, respectively),
and the reduction in SBP by IV-NTG was attenuated (45
to 23 mm Hg, p ¼ 0.002). No patient experienced he-
modynamic collapse during the IV-NTG test. Percentages of
the gradient 50 mm Hg on each provocation maneuver
before and immediately after ASA are shown in Figure 1.
Before ASA, all provocation tests similarly detected gradi-
ents 50 mm Hg indicated for septal reduction therapy. The
gradient provoked by IV-NTG correlated with the post-PVC
gradient both before (r ¼ 0.604, p ¼ 0.003) and after ASA
(r ¼ 0.633, p ¼ 0.002). Of 8 patients in whom Valsalva
maneuver or post-PVC provocation provoked gradients
50 mm Hg immediately after the ﬁrst ASA, all patients
improved to NYHA functional class I or IIs (class I; 7 pa-
tients from IIm [n ¼ 4] or III [n ¼ 3], class IIs; 1 patient
from class III) at 1-year follow-up, and then, 2 patients
presented recurrent symptoms and required repeat ASA after
2 years.
During the 2-year follow-up, changes in HOCM-related
symptoms before and after the ASA procedure are shown
in Figures 2 and 3. At 6-month follow-up, all patients
improved with regard to NYHA functional class
(p <0.0001). Any post-ASA gradients at baseline or prov-
ocation did not correlate with their symptoms. Two patients
received additional ICD implantation. One patient had
documented periprocedural complete atrioventricular block
and sustained ventricular tachycardia associated with
excessive serum concentrations of cibenzoline 11 days later,
and another had a documented syncopal attack and induc-
ible ventricular tachycardia 1 year later. However, neither
had received ICD therapy for ventricular tachyarrhythmias
during the observation periods (5 and 7 years).
The mean follow-up period was 5.1 years (standard de-
viation 3.0 years). KaplaneMeier curves are described in
Figures 4 and 5. Medical treatments including b blockers
and class Ia agents were continued in the all patients during
follow-up. During the observation period of patients with
labile obstruction, there were 10 clinical events, including 4
deaths and 6 cases of recurrent heart failure. Of the 4 pa-
tients who died, 2 showed decreased activities in day-to-day
Figure 3. Number of patients with HOCM-related symptoms. VT/VF;
ventricular tachycardia/ventricular ﬁbrillation.
Figure 4. KaplaneMeier curve for 8-year survival free from all-cause
mortality.
Figure 2. Improvement in NYHA functional class during the 2-year follow-
up. *Within 2 years, 2 patients died because of previously diagnosed
malignancy.
Figure 1. Prevalence of signiﬁcant gradient threshold to septal reduction
therapy with provocation method. All provocation methods provoked
similarly signiﬁcant gradients at baseline. Valsalva maneuver and post-PVC
provoked signiﬁcant gradients in some patients immediately after ASA, but
not IV-NTG.
Figure 5. KaplaneMeier curve for 8-year survival free from cardiovascular
mortality.
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failure (67 and 84 years) with reserved ejection fraction; 2
died because of previously diagnosed malignant diseases
(66 and 81 years); there was no case of sudden cardiac death
or dilated-phase HCM. Of the 6 patients with recurrent heart
failure, 2 developed worsening symptoms associated with
atrial ﬁbrillation and 4 others received repeat ASA because
of residual protrusion adjacent to the previously ablated
950 The American Journal of Cardiology (www.ajconline.org)septum (n ¼ 3) and recanalization of ablated branches (n ¼
1). All repeat cases were successfully treated by ASA and
their symptoms improved to NYHA class I without further
adverse clinical events.
Discussion
The present study systematically investigated the clinical
characteristics and outcome of ASA for those with labile
obstruction and also evaluated the detailed data obtained
from direct pressure recording before and after ASA
incorporating an IV-NTG bolus test.
Nitrate application has been classically used for provo-
cation, in which the main mechanism is thought to be
reduction of LV afterload.12,14e21 Amyl nitrite had been
reported by Wigle in 1963,14 and NTG had been reported by
Braunwald in 1964.15 Septal reduction therapies have been
performed in patients with provoked gradients related to
refractory symptoms.9,10,22 Indeed, although nitrate provo-
cation has been performed in many institutions, to our
knowledge, the present study is the ﬁrst to address the
usefulness of IV-NTG bolus tests during ASA.
Several studies comparing provocation methods have
been reported and comparisons between Valsalva and ex-
ercise,23 amyl nitrite and exercise,19 Valsalva and NTG,15
and between sublingual NTG and dobutamine24 have been
performed during TTE. There was no sufﬁcient evidence to
decide which method was more useful. From the data
among the 3 provocation types used in the present study, the
post-PVC gradient was fairly excessive and gave values
>50 mm Hg even for those who improved at 1-year follow-
up after ASA. To standardize the protocol, we have adopted
extrasystolic potentiation after 1 beat of PVC accompanied
by a compensatory pause. Nevertheless, we could not avoid
large variability in post-PVC gradients.
Vaglio et al reported the clinical characteristics and the
long-term follow-up study in large cohort (n ¼ 415) of
patients with HCM with latent obstruction.25 In comparisons
with the patients, our study population was older and less
severe in septal hypertrophy, and the other characteristics
were comparable. Meanwhile, the present data identiﬁed the
differences in clinical characteristics between labile
obstruction and basal obstruction. In patients with labile
obstruction, the LV wall was less hypertrophied and the
serum concentration of brain natriuretic peptide was less
than in those with basal obstruction. Interestingly, abnormal
response of blood pressure during exercise was observed in
more patients with labile obstruction than with basal
obstruction (47% vs 15%, p ¼ 0.014). Instability of intra-
ventricular obstruction seemed to cause large variability of
the gradient accompanied by the abnormal response as a
characteristic feature of labile obstruction. In previous
studies of HOCM with basal obstruction,3,26e28 the symp-
toms, echocardiographic parameters, and effects of ASA
were comparable to our study population with labile
obstruction, suggesting that severity of symptoms in patients
with HOCM is not correlated with gradient regardless of
being at rest or after provocation. This study demonstrated
that Valsalva maneuver and post-PVC had greater sensi-
tivity to detect the latent gradient immediately after the ASA
procedure than IV-NTG test. It should be kept in mind,however, that the post-ASA gradient cannot be regarded as a
reliable end point even for basal obstruction.29 Regardless of
the gradient, satisfactory ablation is achieved when sufﬁ-
cient ethanol deposits in septal myocardium attributable to
intraventricular obstruction are conﬁrmed by simultaneous
TTE.5 At any rate, latent gradients should be evaluated by
the combination of multiple provocation tests which provide
different types of modiﬁcation to the hypertrophied LV
because it has often been shown that some patients have
susceptibility to one speciﬁc provocation. In this study, we
demonstrated that the IV-NTG test could be available as
another method added to the other provocation tests and
ASA improved the deterioration of hemodynamics during
reduction of LV afterload by IV-NTG.
Finally, we have investigated survival analysis after the
ASA using IV-NTG test in patients with labile obstruction,
compared to those with basal obstruction. Although there
was no difference between the 2 types, the outcomes pre-
sented favorable clinical courses similar to those in pop-
ulations for which previous reports investigated septal
reduction therapy in experienced centers.3,11,27,30 However,
it is unclear what kind of patients with HOCM respond
favorably to ASA alternative to surgical myectomy. The
present study has indicated that ASA was effective at least
for patients with labile obstruction, which accounts for
approximately 20% of drug-refractory symptomatic patients
with HOCM. Direct comparisons should be performed in
further studies to be conducted in a randomized manner.
Major limitations associated with this study were the small
number of patients and the selection bias. Our study popula-
tion included patients with more severe symptoms and a
greater female-to-male ratio, in comparison with other studies
for HOCM with labile obstruction. In general, patients with
HOCMwith labile obstruction have mild symptoms and good
prognosis, and most patients with HCM are male.Acknowledgment: The authors thank Eisei Yamamoto,
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